Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10349884B2 · kind B2 · utility
15Cited by
22References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | Jul 16, 2019 |
| Priority date | — |
| Expiry date | Jan 11, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61B2503/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.